Ifebemtinib tosylate  (Synonyms: BI-853520 tosylate; IN-10018 tosylate)

Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma^[1][2][3][4].

760.75

C₃₅H₃₆F₄N₆O₇S

2761021-80-9

O=C(C1=C(F)C=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C(N(C4)C)=O)=N2)C(OC)=C1)NC5CCN(CC5)C.O=S(O)(C6=CC=C(C)C=C6)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Laszlo, V., et al., (2019). The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of molecular medicine (Berlin, Germany), 97(2), 231–242.  [Content Brief]

  [2]. Verheijen, R. B., et al., (2019). Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted oncology, 14(1), 67–74.  [Content Brief]

  [3]. Tiede, S., et al., (2018). The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7(9), 73.  [Content Brief]

  [4]. Marabelle, A., et al., (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology, 21(10), 1353–1365.  [Content Brief]